Riskpilot← Back to searchSign inGet full accessPANPHARMA NORDIC AS
ASActiveOrg 918719679Glynitveien 25, 1400 SkiWholesale of pharmaceutical and medical goods · NACE 4646Est. 20172 employees
Revenue 2024
NOK 51,8M
+10% vs 2023
EBITDA margin
4.6%
-27% vs 2023
Equity ratio
19.3%
Financial strength
Net profit 2024
NOK 540K
-43% vs 2023
| Revenue | NOK 51,8M | +10% |
| EBITDA | NOK 2,4M | -27% |
| Net profit | NOK 540K | -43% |
| Total assets | NOK 29,8M | +6% |
| Equity | NOK 5,8M | +10% |
| Employees | 2 | — |
Legal name
PANPHARMA NORDIC AS
Org number
918719679
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. mars 2017
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller to styremedlemmer i fellesskap.
Company purpose
Produksjon, salg og distribusjon av farmasøytiske produkter.
Address
Glynitveien 25, 1400 Ski
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 34 819 | 23 660 | 39 822 | 47 345 | 51 846 |
| Staff expenses | −1 734 | −2 191 | −2 456 | −2 447 | −2 735 |
| EBITDA | 2 200 | 1 511 | 1 720 | 3 258 | 2 380 |
| Depreciation & amort. | −6 | −12 | −12 | −9 | −9 |
| EBIT | 2 193 | 1 500 | 1 708 | 3 249 | 2 371 |
| Net financials | −1 146 | −727 | −980 | −2 039 | −1 678 |
| Profit before tax | 1 047 | 773 | 728 | 1 210 | 693 |
| Tax | 231 | 170 | 160 | 266 | 153 |
| Net profit | 816 | 603 | 568 | 944 | 540 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 15 880 | 17 757 | 21 326 | 28 121 | 29 824 |
| Equity | 3 102 | 3 705 | 4 273 | 5 217 | 5 757 |
| Long-term debt | 4 | 4 | 6 | 2 | 5 |
| Short-term debt | 12 773 | 14 048 | 17 047 | 22 902 | 24 062 |
| Total debt | 12 777 | 14 052 | 17 053 | 22 904 | 24 067 |
EBITDA margin
4.6%
This company
15.8%
Market median
-71% vs market
20202024
Equity ratio
19.3%
This company
38.2%
Market median
-49% vs market
20202024
Return on equity
9.4%
This company
18.4%
Market median
-49% vs market
20202024
Net profit margin
1.0%
This company
8.1%
Market median
-88% vs market
20202024
Asset turnover
1.74×
This company
1.12×
Market median
+55% vs market
20202024
Debt / equity
4.18×
This company
0.62×
Market median
-574% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TT Contact Person | Contact Person | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Panpharma S.A. | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PANPHARMA NORDIC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torgeir Tangen | Contact Person | 0 companies |
| Marie-Helene Daniele Dick | Board of Directors | 0 companies |
| Pierre Jean-Yves Emile Moysan | Chairman | 0 companies |